



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,548	09/30/2005	Kunio Kamata	279057US0PCT	3923
22850	7590	09/24/2009		
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER LI, BAO Q	
			ART UNIT 1648	PAPER NUMBER
			NOTIFICATION DATE 09/24/2009	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary	Application No. 10/551,548	Applicant(s) KAMATA ET AL.	
	Examiner BAO LI	Art Unit 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 June 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 10-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 10-13, 20, 22 and 33-35 is/are rejected.
- 7) ☐ Claim(s) 14-19, 21, 23-30 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

This is a response to the amendment filed 06/03/09. Claims 10 and 12 have been amended. Claims 1-9 have been canceled. New claims 31-35 have been added. Claims 10-35 are pending and considered.

Claim Rejections - 35 USC § 102 (withdrawn)

1. The rejection of claims 10-13, 20, 31-32, 34-35 under 35 U.S.C. 102(b) as being anticipated by Hardy et al. (Virology, 1996, Vol. 217, pp. 252-261) has been withdrawn necessitated by Applicants' amendment. Because the prior art does not teach the reaction mixture comprising an antibody against norovirus or sappovirus being mobilized or labeled in the IEM reaction mixture.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. (Maintained) Claims 10-13, 20, 22, 31-35 are still rejected under 35 U.S.C. 103(a) as being unpatentable over Hardy et al. (Virology, 1996, Vol. 217, pp. 252-261) and Kitamoto et al. (J. Clin. Micro. 2002, Vol. 40, No. 7, pp. 2459-2465) necessitated by Applicants' amendment for claim 22.

4. In the response, Applicants submit the following arguments:

5. 1). claims 10-13 and 20 have been amended to have the limitations of claims 14-19;

6. 2). There is no evidence that pH is still at 9.0 to 10.0 after the antibody and sample is 1:1000 diluted;

7. 3). Hardy is silent for the pH being 9.0 to 10.0 for the IEM assay;

8. 4). Office does not provide reasoning explaining why a 1:1000 diluted of rNV particles and antibodies would have a pH within the range of 9.0 to 10.0 required by claims 1 and 31; and

Art Unit: 1648

9. 5). Kitamoto is also silent about a composition having pH ranging from 9.0 to 10.0.

10. Applicants' amendment and argument have been respectfully considered; however, it is not found persuasive to overcome the rejection for the following reasons:

11. 1). Claims 1 and 31 do not have the limitations of claims 14-19 that specify the composition comprising two anti-norovirus antibodies or anti-sappovirus antibodies simultaneously present in the claimed composition, wherein one is labeled and another is immobilized

12. 2). A reasonable broadly interpretation of the scope of the claim 1 and 31 reads the citations regarding the animal globulin, surfactant as well as a water-soluble polymer are only cited as an optional choice rather than a limitation.

13. 3). According to the disclosure by Hardy, et al. in page 253, the rNV is prepared in Tris pH 9.0 and incubated with anti-norovirus antibody diluted in 1:1000. Hardy et al teach to dilute the antibody 1:1000 rather than the rNV in the IEM assay. Therefore, the assertion that the pH may be changed because the 1:1000 dilution of rNV is not applicable in view of the disclosure of the Hardy's reference.

14. 4). Scientifically, it is well known in the art, the regular procedure for doing antibody/antigen reaction, the concentration of an antibody added into a reaction mixture is usually described as a fold of a dilution to its originally stock, because the affinity of an antibody binding to an antigen depends on the affinity of an antibody binding to the antigen epitope, such as the molecular structures of the 3 CDR rather than the protein concentration of an antibody. The antibody added into the sample is always in a very small volume compared to the large volume of the sample comprising an antigen. Sometimes, the dilution is calculated based on the microliter (μ l) added to the large volume such as milliliter (ml) of protein sample (1 ml equals to 1000 μ l). Other the other hand, an antigen added into the reaction mixture is usually measured by a protein concentration rather than dilution.

15. 5). The reference by Nakata et al. in 1987 as Applicants pointed out does not describe the IEM method being performed at any pH. It only cites the IEM can be performed according to another reference drawn to a method for detecting Rotavirus detection by IEM rather than rNV detection.

Art Unit: 1648

16. Without description by Hardy et al. that the rNV is diluted with any other buffer with a low pH before incubating with an antibody, office considers the reaction mixture the IEM is conducted at pH 9-10, the reaction mixture is still considered as a composition comprising anti-norovirus antibody and a norovirus specimen in a Tris alkaline buffer at pH 9.0. See In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977) [PTO can require an applicant to establish that a prior art product does not necessarily possess the characteristics of the claimed product when the prior art and claimed products are identical or substantially identical. While "indirect comparisons, based on established scientific principles, can validly be applied to distinguish a claimed chemical process or product from that disclosed in the prior art," In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 432 (CCPA 1977), the comparisons must be scientifically valid. Patent owner's burden under the circumstances presented herein was described in In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433-434 (CCPA 1977) as follows: Where, as here, the claimed and prior art products are identical or substantially identical, or are produced by identical or substantially identical processes, the PTO can require an applicant to prove that the prior art products do not necessarily or inherently possess the characteristics of his claimed product. . . . Whether the rejection is based on 'inherency' under 35 U.S.C. § 102, or prima facie obviousness' under 35 U.S.C. § 103, jointly or alternatively, the burden of proof is the same, and its fairness is evidenced by the PTO's inability to manufacture products or to obtain and compare prior art products [footnote omitted]. Applicants are encouraged to provide evidence as a Declaration showing that IEM for rNV detection cannot be performed in pH 9.0 – 10.0 and it can be performed only at pH lower than 9-10.0.

17. 6). The disclosure of Kitamoto et al. is the antibody against sappovirus ready known in the art prior to the current Application was filed. The technique for mobilizing or labeling a known antibody directed or indirectly are all well known in the art as evidenced by Hardy et al. or Kitamoto et al. these anti-Norovirus or anti-sappovirus antibodies are all finally labeled with a detectable marker.

18. Therefore, modification of an optimal condition for using or preparing a structure and functionally already known component is generally recognized as being within the level of the ordinary skill in the art, In re Rose, 105 USPQ 237 (CCPA 1995) because it has been held that

Art Unit: 1648

where the general conditions of a claim are disclosed in the prior art, discovering the workable ranges involves only routine skill in the art, *In re Aller*, 105, USPQ 233.

19. Hence, the claimed invention as a whole is still considered to be *prima facie* obvious absence unexpected results.

Claim Rejections - 35 USC § 112 withdrawn

20. The rejection of claim 12 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention has been removed in view of Applicants' persuasive argument that evidence of Good buffer can be prepared at pH 9.0 to 10.0 in the art.

Conclusion

1. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

2. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BAO LI whose telephone number is (571)272-0904. The examiner can normally be reached on 6:30 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bao Qun Li/

Examiner, Art Unit 1648

/Gary B. Nickol /

Supervisory Patent Examiner, Art Unit 1646

Search Notes (continued)

Application/Control No.

10/551,548

Examiner

BAO LI

Applicant(s)/Patent under
Reexamination

KAMATA ET AL.

Art Unit

1648

SEARCHED

Class	Subclass	Date	Examiner

INTERFERENCE SEARCHED

Class	Subclass	Date	Examiner

**SEARCH NOTES
(INCLUDING SEARCH STRATEGY)**

	DATE	EXMR
Double patenting search updated in EAST and eDAN	9/14/2009	BLI
text searchbupdated in WEAT< EAST, STN and Medline	9/14/2009	BLI
prior art issue discussed with G. Nickol.	9/14/2009	BLI